NuCana (NASDAQ:NCNA) Stock Price Down 6.2% – Here’s What Happened

NuCana PLC Sponsored ADR (NASDAQ:NCNA)’s share price fell 6.2% on Monday . The stock traded as low as $3.20 and last traded at $3.20. 123,518 shares were traded during mid-day trading, a decline of 40% from the average session volume of 205,172 shares. The stock had previously closed at $3.41.

Wall Street Analysts Forecast Growth

NCNA has been the topic of a number of research reports. Wall Street Zen upgraded NuCana to a “sell” rating in a research note on Saturday, August 16th. Weiss Ratings restated a “sell (e+)” rating on shares of NuCana in a research report on Wednesday, October 8th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, NuCana presently has an average rating of “Sell”.

NuCana Stock Performance

The company has a 50-day moving average of $4.31 and a 200-day moving average of $12.46. The stock has a market cap of $100,500.00, a price-to-earnings ratio of -0.02 and a beta of 1.51.

NuCana (NASDAQ:NCNA) last posted its quarterly earnings data on Thursday, November 13th. The company reported ($0.10) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.69) by $2.59. As a group, equities research analysts forecast that NuCana PLC Sponsored ADR will post -13.42 EPS for the current year.

About NuCana

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company, through its technology, is developing ProTides medicines to overcome the limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells.